Skip to main content

Table 3 Numbers and proportions of cases of interval cancer and second round screen-detected cancer, and likelihood of presentation, by study group and interval cancer status

From: Impact of false-positive mammography on subsequent screening attendance and risk of cancer

  

Reinvited

Reattending

  

Women (n)

  

Women (n)

  

Study group

Total (100%)

Yes

No

% Yes (95% CI)

Odds ratioa (95% CI)

Yes

No

% Yes (95% CI)

Odds ratioa (95% CI)

All groups

         

   All

113,409

102,772

10,637

90.6 (90.5–90.8)

 

97,062

16,347

85.6 (85.4–85.8)

 

   With interval cancer

375

102

273

27.2 (22.7–31.7)

 

72

303

19.2 (15.2–23.2)

 

   Without interval cancer

113,034

102,670

10,364

90.8 (90.7–91.0)

 

96,990

16,044

85.8 (85.6–86.0)

 

Nonassessed normal

         

   All

108,617

98,561

10,056

90.7 (90.6–90.9)

1.00

93,081

15,536

85.7 (85.5–85.9)

1.00

   With interval cancer

329

97

232

29.5 (24.6–34.4)

 

69

260

21.0 (16.6–25.4)

 

   Without interval cancer

108,288

98,464

9824

90.9 (90.8–91.1)

 

93,012

9824

85.9 (85.7–86.1)

 

Assessed normal

         

   All

4278

3782

496

88.4 (87.4–89.4)

0.78 (0.71–0.86)

3572

706

83.5 (82.4–84.6)

0.84 (0.78–0.92)

   With interval cancer

42

5

37

11.9 (2.1–21.7)

 

3

39

7.1 (0–14.9)

 

   Without interval cancer

4236

3777

459

89.2 (88.2–90.1)

 

3569

667

84.3 (83.2–85.4)

 

Assessed benign

         

   All

514

429

85

83.5 (80.3–86.7)

0.51 (0.41–0.65)

409

105

79.6 (76.1–83.1)

0.65 (0.52–0.81)

   With interval cancer

4

0

4

0

 

0

4

0

 

   Without interval cancer

510

429

81

84.1 (81.0–87.3)

 

409

101

80.2 (76.7–83.7)

 

All assessed

         

   All

4792

4211

581

87.9 (87.0–88.8)

0.74 (0.68–0.81)

3981

811

83.1 (82.0–84.1)

0.82 (0.76–0.89)

   With interval cancer

46

5

41

10.9 (1.9–19.9)

 

3

43

6.5 (0–13.7)

 

   Without interval cancer

4746

4206

540

88.6 (87.7–89.5)

 

3978

768

83.8 (82.8–84.9)

 
  1. a Odds ratios of the likelihood of reinvitation or reattendance among assessed normal, assessed benign or all assessed women versus that in the nonassessed normal group.